CJC-1295 raises trough GH 7.5-fold and IGF-I 45% while preserving pulsatility
Background
Pulsatile growth hormone secretion is considered essential for many of GH's physiological effects, including IGF-I production and anabolic signaling. Endogenous GHRH has an extremely short half-life, limiting its therapeutic application in conditions requiring sustained GH axis stimulation. Short-term GHRH infusions can enhance GH pulsatility and raise IGF-I, but no durable outpatient formulation existed. CJC-1295 was developed as a synthetic GHRH analog engineered to bind permanently to endogenous albumin post-injection, conferring a half-life of approximately 8 days. Prior animal and early human data showed it stimulated GH and IGF-I and enhanced growth in rats, but its effects on the architecture of GH pulsatility under continuous stimulation remained uncharacterized.
Study Design
Healthy men aged 20–40 years received a single subcutaneous injection of either 60 µg/kg or 90 µg/kg CJC-1295. GH pulsatility was assessed via 20-minute interval blood sampling over an overnight 12-hour period conducted before and 1 week after injection. The primary endpoints were GH secretory pulse frequency, pulse magnitude, basal (trough) GH levels, mean GH levels, and serum IGF-I concentrations. No placebo arm is described in the abstract; within-subject pre/post comparisons were the primary analytic frame.
Results
GH secretion was broadly elevated following CJC-1295 administration, yet the architecture of pulsatility was preserved: pulse frequency and pulse magnitude were statistically unaltered. The dominant mechanism of GH elevation was a dramatic rise in basal (trough) GH levels rather than changes to discrete secretory bursts.
Basal (trough) GH levels increased 7.5-fold (p < 0.0001), driving a 46% rise in mean GH (p < 0.01) and a 45% rise in IGF-I (p < 0.001).
No significant difference was detected between the 60 µg/kg and 90 µg/kg dose groups, suggesting a plateau or ceiling in response within this dose range. Notably, the magnitude of IGF-I elevation did not correlate with any individual parameter of GH secretion — pulse height, trough GH, or mean GH — indicating the relationship between continuous GHRH stimulation and downstream IGF-I production is not straightforwardly linear.
Key Findings
- Basal (trough) GH levels rose 7.5-fold after a single CJC-1295 injection (p < 0.0001)
- Mean GH levels increased 46% over the 12-hour sampling window (p < 0.01)
- IGF-I levels rose 45% one week post-injection (p < 0.001)
- GH pulse frequency and magnitude were statistically unchanged — pulsatility preserved
- No significant difference in response between 60 µg/kg and 90 µg/kg doses
Why It Matters
Continuous GHRH stimulation does not blunt GH pulsatility — a concern that had been a theoretical barrier to long-acting GHRH therapeutics. For clinicians and researchers, this validates the mechanistic rationale for long-acting GHRH analogs in patients with intact pituitary GH secretory capacity, such as those with GH deficiency of hypothalamic origin. For practitioners evaluating peptide protocols, the finding that trough GH — not pulse amplitude — is the primary driver of IGF-I elevation reframes how efficacy should be assessed: a single weekly injection sustaining elevated basal GH for days may be clinically sufficient. The absence of a dose-response difference between 60 and 90 µg/kg also has practical protocol implications, suggesting higher doses in this range confer no additional benefit.
TitrateLab articles covering CJC-1295
Written by TitrateLab, separately from the study summarized above.
